Zealand Pharma announces first patient dosed in Phase 2 trial with long-acting GLP-1/glucagon dual agonist in obesity/diabetesGlobeNewsWire • 06/24/20
Zealand Pharma major shareholder announcement: Sunstone Life Science VenturesGlobeNewsWire • 06/23/20
Zealand Pharma announces completion of directed issue and private placement of 2,684,461 new ordinary sharesGlobeNewsWire • 06/17/20
Zealand Pharma announces directed issues and private placements of up to approx. 2.68 million new ordinary sharesGlobeNewsWire • 06/17/20
Zealand Pharma presents clinical and non-clinical evidence for dasiglucagon rescue therapy at the 80th Scientific Sessions of the American Diabetes AssociationGlobeNewsWire • 06/14/20
Zealand Pharma presents elaborated results on the use of regular human insulin delivered by V-Go® in older adults with type 2 diabetes, at the 80th Scientific Sessions of the American Diabetes AssociationGlobeNewsWire • 06/13/20
Zealand Pharma to leverage Intomics bioinformatics platform within peptide drug discovery and development processGlobeNewsWire • 06/10/20
Zealand Pharma (ZEAL) increases its share capital as a consequence of exercise of employee warrantsGlobeNewsWire • 05/26/20
Zealand Pharma announces FDA acceptance of New Drug Application for the dasiglucagon HypoPal® rescue pen for treatment of severe hypoglycemiaGlobeNewsWire • 05/22/20
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated personsGlobeNewsWire • 05/22/20
Zealand Pharma A/S (ZEAL) CEO Emmanuel Dulac on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/14/20
Zealand Pharma files New Drug Application with U.S. FDA for dasiglucagon HypoPal® rescue pen, secures DKK 137 million in additional investment, and accelerates readiness of U.S.GlobeNewsWire • 05/14/20
Transactions in Zealand Pharma - shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated personsGlobeNewsWire • 04/27/20
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated personsGlobeNewsWire • 04/20/20
Zealand Pharma grants warrants and restricted stock units under the employee warrant program and management long-term incentive programGlobeNewsWire • 04/15/20
Zealand Pharma presents positive clinical and health economic outcome data with use of regular human insulin delivered by the V-Go in adults with type 2 diabetesGlobeNewsWire • 04/15/20
Zealand Pharma increases its share capital as a consequence of exercise of employee warrantsGlobeNewsWire • 04/15/20
Transactions in Zealand Pharma (ZEAL) shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated personsGlobeNewsWire • 04/08/20
Zealand Pharma major shareholder announcement: Wellington Management Group LLPGlobeNewsWire • 04/06/20
